Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2022.6192
Abstract: This post hoc analysis of 6 randomized, double-blind, placebo-controlled trials assesses the efficacy and safety of dupilumab in patients with erythrodermic atopic dermatitis. read more here.
Keywords: patients erythrodermic; erythrodermic atopic; dupilumab patients; efficacy safety ... See more keywords
P047 Successful treatment with dupilumab in patients with bullous pemphigoid and concomitant atopy
Sign Up to like & getrecommendations! Published in 2025 at "British Journal of Dermatology"
DOI: 10.1093/bjd/ljaf085.075
Abstract: Dupilumab is a humanized antibody that inhibits interleukin (IL)-4/IL-13 signalling. It is approved for the treatment of multiple type 2 inflammatory diseases, including atopic dermatitis. The involvement of IgE antibodies and eosinophils also appears to… read more here.
Keywords: patients bullous; treatment; atopy; dupilumab patients ... See more keywords
Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cutaneous Medicine and Surgery"
DOI: 10.1177/12034754221130969
Abstract: Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and psychosocial comorbidities decreasing the quality of life for many patients. Dupilumab, a human monoclonal antibody that blocks interleukins IL-4 and IL-13,… read more here.
Keywords: review meta; meta analysis; systematic review; analysis ... See more keywords